N,N-di(aryl) cyclic urea derivatives as anti-coagulants

Abstract

N,N-di(aryl) cyclic urea derivatives, such as the compounds of the following formula: <IMAGE> (III) wherein R1 is -C(NH)NH2, -C(NH)N(H)OR11, -C(NH)N(H)C(O)R9, or -C(NH)N(H)C(O)OR11; R2 and R3 are independently hydrogen, halo, lower alkyl, lower haloalkyl, aryl, -OR11, -C(O)OR11, -C(O)N(R11)R12, -N(R11)R12, -N(H)C(O)R11, or -N(H)S(O)2R11; R4 is halo, lower haloalkyl, imidazolyl, -C(NH)NH2, -C(NH)NHOR11, -C(NH)N(H)C(O)R9, -C(NH)N(H)C(O)OR11, -OR11, -C(O)R13, -(CH2)nC(O)OR11 (where n is 0 to 6), -C(O)N(R11)R12, or -N(R11)R12; R7 and R8 are independently hydrogen, lower alkyl, lower haloalkyl, 4-pyridinyl, -C(O)OR11, -C(O)N(R11)R12, or aryl (optionally substituted by one or more substituents selected from the group consisting of halo, hydroxy, lower alkyl, lower haloalkyl, lower alkoxy and -N(R11)R12); R11 and R12 are independently hydrogen, lower alkyl, aryl or lower aralkyl; or R13 is pyrrolidinyl, 4-morpholinyl, piperazinyl, N-methylpiperazinyl, or piperidinyl; or a pharmaceutically acceptable salt thereof, are disclosed herein as being inhibitors of factor Xa and thereby being useful as anticoagulants.

What is claimed is: 
     
       1. A method of treating a human having thrombotic complications associated with myocardial infarction, deep vein thrombosis following orthopedic surgery, transient ischemic attack, coronary artery bypass graft, percutaneous transluminal coronary angioplasty, acute promyelocytic leukemia, diabetes, multiple myelomas, septic shock, purpura fulminanas, adult respiratory distress syndrome, angina, and aortic valve or vascular prosthesis, which method comprises administering to a human in need thereof a therapeutically effective amount of a compound selected from the group consisting of the following formulae: ##STR11## wherein: A is --C(R 5 )R 6  --(CH 2 ) m  --C(R 9 )(R 10 )-- (where m is 0 to 2); R 1  is --C(NH)NH 2 , --C(NH)N(H)OR 11 , --C(NH)N(H)C(O)R 9 , or --C(NH)N(H)C(O)OR 11  ;   R 2  and R 3  are the same or different and are selected from the group consisting of independently hydrogen, halo, lower alkyl, lower haloalkyl, aryl, --OR 11 , --C(O)OR 11 , --C(O)N(R 11 )R 12 , --N(R 11 )R 12 , --N(H)C(O)R 11 , and --N(H)S(O) 2  R 11  ;   R 4  is halo, lower haloalkyl, imidazolyl, --C(NH)NH 2 , --C(NH)NHOR 11 , --C(NH)N(H)C(O)R 9 , --C(NH)N(H)C(O)OR 11 , --OR 11 , --C(O)R 13 , --(CH 2 ) n  C(O)OR 11  (where n is 0 to 6), --C(O)N(R 11 )R 12 , or --N(R 11 )R 12  ;   R 5 , R 6 , R 9  and R 10  are independently hydrogen, halo, lower alkyl, lower haloalkyl, 4-pyridinyl, --OR 11 , --C(O)OR 11 , --C(O)N(R 11 )R 12 , or aryl (optionally substituted by one or more substituents selected from the group consisting of halo, hydroxy, lower alkyl, lower haloalkyl, lower alkoxy and --N(R 11 )R 12 ); R 7  and R 8  are independently hydrogen, lower alkyl, lower haloalkyl, 4-pyridinyl, --C(O)OR 11 , --C(O)N(R 11 )R 12 , or aryl (optionally substituted by one or more substituents selected from the group consisting of halo, hydroxy, lower alkyl, lower haloalkyl, lower alkoxy and --N(R 11 )R 12 );   R 11  and R 12  are independently hydrogen, lower alkyl, aryl or lower aralkyl; or   R 13  is pyrrolidinyl, 4-morpholinyl, piperazinyl, N-methylpiperazinyl, or piperidinyl; or a pharmaceutically acceptable salt thereof.